HSA Registration Support Initiative for Unregistered Medical Devices

The Health Sciences Authority (HSA) Registration Support Initiative helps clinically important unregistered medical devices move from Singapore's Special Access Route (SAR) toward formal registration. HSA's page was updated on 26 August 2026 and describes the initiative as separate from ordinary SAR applications; it addresses low-volume or low-price devices and legacy devices for which registration has been deterred by cost or dossier burden (HSA, updated 26 Aug 2026).

Why HSA introduced the initiative

SAR allows patient access to unregistered medical devices in exceptional circumstances, but HSA says it is not intended to be a long-term supply mechanism. The new initiative is intended to create a more sustainable supply pathway for devices that continue to meet important clinical needs in Singapore. It does not convert every SAR device into a registered device and does not remove HSA's registration assessment (HSA, 28 August 2026).

HSA identifies the central support as a waiver of evaluation fees for eligible devices, reducing the regulatory cost of registration. The initiative is intended to help address needs in small patient populations, but it is not guaranteed registration: HSA still assesses the product through the applicable registration route. Eligibility is limited to devices meeting either of two published routes: higher-risk Class C or D devices that are essential or life-saving in rare clinical situations, non-novel, used for at least five years and supplied at low prices or quantities; or legacy devices with no registered alternatives, at least three years of local SAR clinical use through two consecutive GN-26 or GN-27 applications, and more than ten years' established use (HSA, updated 26 Aug 2026).

How clinicians and suppliers initiate support

Clinicians are invited to identify devices in their practice that may qualify, complete a Clinical Justification and Endorsement Form, and connect with the device supplier to initiate the process. The initiative is therefore designed around a clinical need identified in practice and a supplier willing to pursue formal registration; it is not described as a direct patient-application or household subsidy scheme (HSA, 28 August 2026).

Public healthcare institutions obtain endorsement from their Chairman of Medical Board; private institutions and clinics use the Academy of Medicine, Singapore, which begins accepting endorsement requests from 1 October 2026. Suppliers submit the endorsed clinical form with supporting evidence to HSA during the window. HSA says it will notify companies of fee-waiver eligibility by April of the following year, and eligible companies must submit the product-registration application within one year of notification (HSA, updated 26 Aug 2026).

Application windows and interpretation

The inaugural application window remains open until 31 December 2026. After that, HSA says the initiative will open annually from 1 October to 31 December. The date is an application-window schedule, not a promised approval date or a guarantee that a submitted device will be registered (HSA, 28 August 2026).

This initiative should be kept separate from ordinary medical-device registration, SAR access, and patient financial assistance. Its published scope is regulatory support for eligible clinically important unregistered devices, with evaluation-fee relief and a clinician–supplier initiation route. The public page provides only an abstract of the initiative, so healthcare professionals and suppliers must consult the detailed HSA/MOH materials for current criteria and requirements before relying on the summary (HSA, 28 August 2026).

Public information and professional-access boundary

HSA’s public announcement labels the material as an abstract of a Dear Healthcare Professional Letter (DHCPL). It directs dentists, medical doctors and pharmacists to the Health Professionals Portal (HPP), where they can sign in with Singpass, choose their profession, open “Useful links”, and access the MOH Alert System’s “Med Device Alerts” section. This distinction matters for both applicants and retrieval: the public HSA page supports the existence, broad purpose, windows, criteria summary and application route, but it is not the complete DHCPL or a substitute for the supporting forms. A clinician or company should therefore use the detailed HSA materials and current submission instructions when determining whether a particular device satisfies every qualification condition. The initiative remains a regulatory registration-support pathway; access to the HPP or a successful submission does not itself establish a fee waiver, formal registration or permission to supply outside the applicable SAR and registration rules (HSA, updated 26 August 2026; HSA DHCPL abstract, 28 August 2026).